Actively Recruiting
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Led by Second Affiliated Hospital of Nanchang University · Updated on 2026-02-02
30
Participants Needed
1
Research Sites
51 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are: Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?
CONDITIONS
Official Title
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) classified as T3-4N1-2M0
- Tumor deemed initially unresectable after multidisciplinary team evaluation
- Age between 18 and 85 years old
- ECOG performance status score of 0 to 1
- No known EGFR or ALK mutations
You will not qualify if you...
- Participation in another clinical study using investigational products within the past 3 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanchang City, Jiangxi Province
Nanchang, Jiangxi, China, 330000
Actively Recruiting
Research Team
J
jing cai Jing Cai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here